NCT00061646View on ClinicalTrials.gov

Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2003

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

ABT-510/Thrombospondin-1 mimetic

DRUG

Carboplatin/Taxol

Trial Locations (4)

33176

Oncology-Hematology Group of South Florida, Miami

38120

The West Cancer Clinic, Memphis

60637-1470

University of Chicago, Chicago

53792-5666

University of Wisconsin, Madison

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00061646 - Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter